Cargando…
Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional au...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096329/ https://www.ncbi.nlm.nih.gov/pubmed/33910450 http://dx.doi.org/10.1080/19336896.2021.1917289 |
_version_ | 1783688138840866816 |
---|---|
author | Kulichikhin, Konstantin Y. Fedotov, Sergei A. Rubel, Maria S. Zalutskaya, Natalia M. Zobnina, Anastasia E. Malikova, Oksana A. Neznanov, Nikolay G. Chernoff, Yury O. Rubel, Aleksandr A. |
author_facet | Kulichikhin, Konstantin Y. Fedotov, Sergei A. Rubel, Maria S. Zalutskaya, Natalia M. Zobnina, Anastasia E. Malikova, Oksana A. Neznanov, Nikolay G. Chernoff, Yury O. Rubel, Aleksandr A. |
author_sort | Kulichikhin, Konstantin Y. |
collection | PubMed |
description | Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional autonomy, making a patient completely dependent on family members and/or healthcare workers. Critical features of AD are pathological polymerization of Aβ peptide and microtubule-associated protein tau, accompanied by alterations of their conformations and resulting in accumulation of cross-β fibrils (amyloids) in human brains. AD apparently progresses asymptomatically for years or even decades before the appearance of symptoms. Therefore, development of the early AD diagnosis at a pre-symptomatic stage is essential for potential therapies. This review is focused on current and potential molecular tools (including non-invasive methods) that are based on detection of amyloidogenic proteins and can be applicable to early diagnosis of AD. Abbreviations: Aβ – amyloid-β peptide; AβO – amyloid-β oligomers; AD – Alzheimer’s disease; ADRDA – Alzheimer’s Disease and Related Disorders Association; APH1 - anterior pharynx defective 1; APP – amyloid precursor protein; BACE1 – β-site APP-cleaving enzyme 1; BBB – brain blood barrier; CJD - Creutzfeldt-Jakob disease; CRM – certified reference material; CSF – cerebrospinal fluid; ELISA – enzyme-linked immunosorbent assay; FGD – (18)F-fluorodesoxyglucose (2-deoxy-2-[(18)F]fluoro-D-glucose); IP-MS – immunoprecipitation-mass spectrometry assay; MCI – mild cognitive impairment; MDS – multimer detection system; MRI – magnetic resonance imaging; NIA-AA – National Institute on Ageing and Alzheimer’s Association; NINCDS – National Institute of Neurological and Communicative Disorders and Stroke; PEN2 – presenilin enhancer 2; PET – positron emission tomography; PiB – Pittsburgh Compound B; PiB-SUVR - PIB standardized uptake value ratio; PMCA – Protein Misfolding Cycling Amplification; PrP – Prion Protein; P-tau – hyperphosphorylated tau protein; RMP – reference measurement procedure; RT-QuIC - real-time quaking-induced conversion; SiMoA – single-molecule array; ThT – thioflavin T; TSEs – Transmissible Spongiform Encephslopathies; T-tau – total tau protein |
format | Online Article Text |
id | pubmed-8096329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-80963292021-05-13 Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins Kulichikhin, Konstantin Y. Fedotov, Sergei A. Rubel, Maria S. Zalutskaya, Natalia M. Zobnina, Anastasia E. Malikova, Oksana A. Neznanov, Nikolay G. Chernoff, Yury O. Rubel, Aleksandr A. Prion Review Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional autonomy, making a patient completely dependent on family members and/or healthcare workers. Critical features of AD are pathological polymerization of Aβ peptide and microtubule-associated protein tau, accompanied by alterations of their conformations and resulting in accumulation of cross-β fibrils (amyloids) in human brains. AD apparently progresses asymptomatically for years or even decades before the appearance of symptoms. Therefore, development of the early AD diagnosis at a pre-symptomatic stage is essential for potential therapies. This review is focused on current and potential molecular tools (including non-invasive methods) that are based on detection of amyloidogenic proteins and can be applicable to early diagnosis of AD. Abbreviations: Aβ – amyloid-β peptide; AβO – amyloid-β oligomers; AD – Alzheimer’s disease; ADRDA – Alzheimer’s Disease and Related Disorders Association; APH1 - anterior pharynx defective 1; APP – amyloid precursor protein; BACE1 – β-site APP-cleaving enzyme 1; BBB – brain blood barrier; CJD - Creutzfeldt-Jakob disease; CRM – certified reference material; CSF – cerebrospinal fluid; ELISA – enzyme-linked immunosorbent assay; FGD – (18)F-fluorodesoxyglucose (2-deoxy-2-[(18)F]fluoro-D-glucose); IP-MS – immunoprecipitation-mass spectrometry assay; MCI – mild cognitive impairment; MDS – multimer detection system; MRI – magnetic resonance imaging; NIA-AA – National Institute on Ageing and Alzheimer’s Association; NINCDS – National Institute of Neurological and Communicative Disorders and Stroke; PEN2 – presenilin enhancer 2; PET – positron emission tomography; PiB – Pittsburgh Compound B; PiB-SUVR - PIB standardized uptake value ratio; PMCA – Protein Misfolding Cycling Amplification; PrP – Prion Protein; P-tau – hyperphosphorylated tau protein; RMP – reference measurement procedure; RT-QuIC - real-time quaking-induced conversion; SiMoA – single-molecule array; ThT – thioflavin T; TSEs – Transmissible Spongiform Encephslopathies; T-tau – total tau protein Taylor & Francis 2021-04-29 /pmc/articles/PMC8096329/ /pubmed/33910450 http://dx.doi.org/10.1080/19336896.2021.1917289 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kulichikhin, Konstantin Y. Fedotov, Sergei A. Rubel, Maria S. Zalutskaya, Natalia M. Zobnina, Anastasia E. Malikova, Oksana A. Neznanov, Nikolay G. Chernoff, Yury O. Rubel, Aleksandr A. Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title | Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title_full | Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title_fullStr | Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title_full_unstemmed | Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title_short | Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins |
title_sort | development of molecular tools for diagnosis of alzheimer’s disease that are based on detection of amyloidogenic proteins |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096329/ https://www.ncbi.nlm.nih.gov/pubmed/33910450 http://dx.doi.org/10.1080/19336896.2021.1917289 |
work_keys_str_mv | AT kulichikhinkonstantiny developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT fedotovsergeia developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT rubelmarias developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT zalutskayanataliam developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT zobninaanastasiae developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT malikovaoksanaa developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT neznanovnikolayg developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT chernoffyuryo developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins AT rubelaleksandra developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins |